High patient satisfaction for ocular hypotensives

Article

Glaucoma and ocular hypertension (OHT) patients are highly satisfied with ocular hypertensives, claims a recent investigation.

Glaucoma and ocular hypotension patients are highly satisfied with ocular hypotensives, claims a recent investigation.

A prospective, observational, cohort study, led by Professor Helen Danesh-Meyer, Department of Ophthalmology, University of Auckland, New Zealand, included 2541 patients with glaucoma or ocular hypotension. The Treatment Impact Patient Satisfaction Scale (TIPSS) was mailed to all patients during a three-month study period.

The questionnaire evaluated patient demographics topical ocular hypotensive use, number of medications used, frequency of administration, ease of use, class of medication, presence/severity of side effects, impact on quality of life and patient satisfaction. The main outcome measure was patient satisfaction and this was determined via univariate and multivariate analyses.

Of the patients who responded to the questionnaire, almost 80% claimed they were either 'very satisfied' or 'satisfied' with topical ocular hypotensives. Factors that affected patient satisfaction were identified as satisfaction with frequency of eye drop use, subjective convenience and ease of administration.

Overall, glaucoma and ocular hypotension patients are satisfied with topical ocular hypotensive medications. However, patient satisfaction could be further improved by focusing on medication convenience and ease of administration.

The abstract can be found in the latest issue of Clinical and Experimental Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.